Citi raises target for AstraZeneca stock to GBp 18,600

Citi raised its AstraZeneca target from GBp 17,800 to GBp 18,600 on October 6, 2026, while retaining a Buy rating, according to TipRanks. At GBp 11,958 on the London listing on October 14, 2026, the new target lies 55.54 percent above the share price. AstraZeneca stock was trading at EUR 141.88 at Lang & Schwarz on October 14, 2026 at 2:13 p.m. CEST.

Stock remains below its yearly high

The London price stood 23.99 percent below the GBp 15,732 52-week high and 20.88 percent above the GBp 9,892 low on October 14, 2026. That spread places the stock closer to the lower end of its annual range than to the upper boundary, despite the fresh Citi target.

AstraZeneca's London quote was GBp 11,958, with a trading volume of 467,871 shares against an average volume of 3,375,257 shares. The quoted price-to-earnings ratio was 23.75, giving valuation more weight than the single-day price indication in the euro market.

Valuation and October reporting date

AstraZeneca had a market capitalization of GBP 185.5 billion on October 14, 2026, while its trailing price-to-earnings ratio was 23.75 and its dividend yield was 2.00 percent. These figures describe a large, profitable pharmaceutical company, but the target revision also shows how much of the current discussion remains tied to pipeline execution.

Yahoo Finance identifies AstraZeneca as LSE:AZN and a FTSE 100 pharmaceutical company. StockAnalysis lists October 30, 2026 as the next earnings date, making the upcoming results the next scheduled test for the valuation and the analyst target.

Euro quote at Lang & Schwarz

AstraZeneca stock was trading at EUR 141.88 at Lang & Schwarz on October 14, 2026 at 2:13 p.m. CEST. The London quote was GBp 11,958 at 1:24 p.m. BST, while the 52-week range was GBp 9,892 to GBp 15,732. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.

Market context: Market report FTSE 100.

More news and analyses on AstraZeneca stock